Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TransMedics Group, Inc.TMDX · Entity 4261 | Director · President & CEO | July 10, 2026 | July 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TransMedics Group, Inc.
Report date July 10, 2026 · Filed July 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 171,093 |
Reported balance
After 2026-07-10 transaction · row 1
1 source rowRow 1 · 2026-07-10 · Grant · Acquired 49,669 · Balance 171,093 F1: Consists of 49,669 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $71.23 · Expires 2036-07-10 | Direct | 112,984 |
Reported balance
After 2026-07-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-10 · Grant · Acquired 112,984 · Balance 112,984 F3: The option vests at a rate of 2.0833% of the total number of shares subject to the option each month following April 10, 2026 until the option is fully vested on April 10, 2030, subject to continued service. |
| Common StockSEC Table I · non-derivative | IndirectBy the Waleed H. Hassanein Revocable Trust | 345,009 |
Reported balance
Holding disclosure · report date 2026-07-10 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 345,009 F2: Reflects a prior transfer of 150,000 shares of the Issuer's common stock from the Waleed H. Hassanein Revocable Trust to the Hassanein 2026 Qualified Annuity Trust. The transfer constituted only a change in the form of beneficial ownership and was exempt under Rule 16a-13 of the Securities Exchange Act of 1934, as amended. |
| Common StockSEC Table I · non-derivative | IndirectBy the Hassanein 2026 Qualified Annuity Trust | 150,000 |
Reported balance
Holding disclosure · report date 2026-07-10 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 150,000 F2: Reflects a prior transfer of 150,000 shares of the Issuer's common stock from the Waleed H. Hassanein Revocable Trust to the Hassanein 2026 Qualified Annuity Trust. The transfer constituted only a change in the form of beneficial ownership and was exempt under Rule 16a-13 of the Securities Exchange Act of 1934, as amended. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of 49,669 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F2: Reflects a prior transfer of 150,000 shares of the Issuer's common stock from the Waleed H. Hassanein Revocable Trust to the Hassanein 2026 Qualified Annuity Trust. The transfer constituted only a change in the form of beneficial ownership and was exempt under Rule 16a-13 of the Securities Exchange Act of 1934, as amended.
F3: The option vests at a rate of 2.0833% of the total number of shares subject to the option each month following April 10, 2026 until the option is fully vested on April 10, 2030, subject to continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 14, 2024 Filed Jun 17, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 8,625 | $13.28 | $114,540.00 |
DisclosureSEC source: 0000950170-24-074284 · ownership.xml · nonDerivative · entry 1 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,268 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,625 | $0.00 Strike: $13.28 | $0.00 |
DisclosureSEC source: 0000950170-24-061700 · ownership.xml · derivative · entry 7 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,375 Underlying: Common Stock · 8,625 shares Expires 2032-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F6 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 22, 2026. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 744 | $136.26 | $101,377.44 |
DisclosureSEC source: 0000950170-24-061700 · ownership.xml · nonDerivative · entry 5 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,643 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $136.06 to $136.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 5,481 | $135.54 | $742,894.74 |
DisclosureSEC source: 0000950170-24-061700 · ownership.xml · nonDerivative · entry 4 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,387 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $135.06 to $136.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 2,100 | $134.69 | $282,849.00 |
DisclosureSEC source: 0000950170-24-061700 · ownership.xml · nonDerivative · entry 3 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,868 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $134.05 to $135.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 300 | $133.42 | $40,026.00 |
DisclosureSEC source: 0000950170-24-061700 · ownership.xml · nonDerivative · entry 2 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,968 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $133.07 to $133.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 8,625 | $13.28 | $114,540.00 |
DisclosureSEC source: 0000950170-24-061700 · ownership.xml · nonDerivative · entry 1 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,268 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| May 06, 2024 Filed May 8, 2024 20:31 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $13.28 | $0.00 |
DisclosureSEC source: 0000950170-24-055785 · ownership.xml · derivative · entry 4 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 148,000 Underlying: Common Stock · 30,000 shares Expires 2032-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F3 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 22, 2026. Read SEC document |
| May 06, 2024 Filed May 8, 2024 20:31 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 30,000 | $130.07 | $3,902,100.00 |
DisclosureSEC source: 0000950170-24-055785 · ownership.xml · nonDerivative · entry 2 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,643 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $130.00 to $130.235, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 06, 2024 Filed May 8, 2024 20:31 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 30,000 | $13.28 | $398,400.00 |
DisclosureSEC source: 0000950170-24-055785 · ownership.xml · nonDerivative · entry 1 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,643 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| May 02, 2024 Filed May 3, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 82 | $122.67 | $10,058.94 |
DisclosureSEC source: 0000950170-24-052964 · ownership.xml · nonDerivative · entry 10 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,643 Read SEC document |
| May 02, 2024 Filed May 3, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 6,222 | $122.16 | $760,079.52 |
DisclosureSEC source: 0000950170-24-052964 · ownership.xml · nonDerivative · entry 9 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,725 F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $121.66 to $122.51, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 02, 2024 Filed May 3, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 6,140 | $120.64 | $740,729.60 |
DisclosureSEC source: 0000950170-24-052964 · ownership.xml · nonDerivative · entry 8 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,947 F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $120.22 to $120.995, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 56,000 | $0.00 Strike: $13.28 | $0.00 |
DisclosureSEC source: 0000950170-24-052964 · ownership.xml · derivative · entry 12 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178,000 Underlying: Common Stock · 56,000 shares Expires 2032-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F8 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 22, 2026. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 22,500 | $120.25 | $2,705,625.00 |
DisclosureSEC source: 0000950170-24-052964 · ownership.xml · nonDerivative · entry 7 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,087 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $120.00 to $120.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 23,500 | $114.17 | $2,682,995.00 |
DisclosureSEC source: 0000950170-24-052964 · ownership.xml · nonDerivative · entry 6 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,587 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $114.00 to $114.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 6,800 | $110.00 | $748,000.00 |
DisclosureSEC source: 0000950170-24-052964 · ownership.xml · nonDerivative · entry 5 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,087 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 424 | $107.57 | $45,609.68 |
DisclosureSEC source: 0000950170-24-052964 · ownership.xml · nonDerivative · entry 4 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 126,887 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $107.56 to $107.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 91 | $106.51 | $9,692.41 |
DisclosureSEC source: 0000950170-24-052964 · ownership.xml · nonDerivative · entry 3 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 127,311 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 2,685 | $105.56 | $283,428.60 |
DisclosureSEC source: 0000950170-24-052964 · ownership.xml · nonDerivative · entry 2 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 127,402 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $105.50 to $106.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 56,000 | $13.28 | $743,680.00 |
DisclosureSEC source: 0000950170-24-052964 · ownership.xml · nonDerivative · entry 1 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,087 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| April 17, 2024 Filed Apr 18, 2024 20:51 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $13.28 | $0.00 |
DisclosureSEC source: 0000950170-24-045620 · ownership.xml · derivative · entry 4 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 234,000 Underlying: Common Stock · 4,000 shares Expires 2032-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F3 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 22, 2026. Read SEC document |
| April 17, 2024 Filed Apr 18, 2024 20:51 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 4,000 | $95.12 | $380,480.00 |
DisclosureSEC source: 0000950170-24-045620 · ownership.xml · nonDerivative · entry 2 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,087 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $95.07 to $95.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 17, 2024 Filed Apr 18, 2024 20:51 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 4,000 | $13.28 | $53,120.00 |
DisclosureSEC source: 0000950170-24-045620 · ownership.xml · nonDerivative · entry 1 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,087 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| April 10, 2024 Filed Apr 12, 2024 20:05 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $13.28 | $0.00 |
DisclosureSEC source: 0000950170-24-044020 · ownership.xml · derivative · entry 4 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 238,000 Underlying: Common Stock · 12,000 shares Expires 2032-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F3 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 22, 2026. Read SEC document |
| April 10, 2024 Filed Apr 12, 2024 20:05 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 12,000 | $95.09 | $1,141,080.00 |
DisclosureSEC source: 0000950170-24-044020 · ownership.xml · nonDerivative · entry 2 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,087 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $95.00 to $95.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 10, 2024 Filed Apr 12, 2024 20:05 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 12,000 | $13.28 | $159,360.00 |
DisclosureSEC source: 0000950170-24-044020 · ownership.xml · nonDerivative · entry 1 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,087 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 22:00 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | GrantStock Option (Right to Buy) · Derivative | 56,645 | $0.00 Strike: $83.14 | $0.00 |
DisclosureSEC source: 0000950170-24-021329 · ownership.xml · derivative · entry 2 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,645 Underlying: Common Stock · 56,645 shares Expires 2034-02-23 F2 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares subject to the option each month following February 23, 2024 until the option is fully vested on February 23, 2028, subject to continued service. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 22:00 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | GrantCommon Stock | 36,755 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-021329 · ownership.xml · nonDerivative · entry 1 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 543,446 F1 · shares: Consists of 36,755 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 100 | $75.28 | $7,528.00 |
DisclosureSEC source: 0000950170-23-068200 · ownership.xml · nonDerivative · entry 3 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 506,691 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on December 14, 2022. F4 · balance_after: Includes 37,332 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 4,475 | $74.61 | $333,879.75 |
DisclosureSEC source: 0000950170-23-068200 · ownership.xml · nonDerivative · entry 2 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 506,791 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on December 14, 2022. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $74.24 to $75.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 2,925 | $74.06 | $216,625.50 |
DisclosureSEC source: 0000950170-23-068200 · ownership.xml · nonDerivative · entry 1 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 511,266 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on December 14, 2022. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $73.23 to $74.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 07, 2023 Filed Nov 10, 2023 00:00 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 15,000 | $64.32 | $964,800.00 |
DisclosureSEC source: 0000950170-23-062269 · ownership.xml · nonDerivative · entry 1 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 514,191 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on December 14, 2022. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $64.06 to $64.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 37,332 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 20:31 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 1,082 | $68.95 | $74,603.90 |
DisclosureSEC source: 0000950170-23-046753 · ownership.xml · nonDerivative · entry 4 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 529,191 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on December 14, 2022. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $68.85 to $69.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F5 · balance_after: Includes 37,332 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 20:31 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 4,310 | $68.55 | $295,450.50 |
DisclosureSEC source: 0000950170-23-046753 · ownership.xml · nonDerivative · entry 3 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 530,273 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on December 14, 2022. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $67.85 to $68.845, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 20:31 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 2,045 | $67.35 | $137,730.75 |
DisclosureSEC source: 0000950170-23-046753 · ownership.xml · nonDerivative · entry 2 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 534,583 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on December 14, 2022. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $66.85 to $67.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 20:31 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 63 | $65.63 | $4,134.69 |
DisclosureSEC source: 0000950170-23-046753 · ownership.xml · nonDerivative · entry 1 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 536,628 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on December 14, 2022. Read SEC document |
| August 01, 2023 Filed Aug 4, 2023 00:01 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 2,183 | $93.77 | $204,699.91 |
DisclosureSEC source: 0000950170-23-038269 · ownership.xml · nonDerivative · entry 3 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 536,691 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on December 14, 2022. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $93.40 to $94.09, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F5 · balance_after: Includes 37,332 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 01, 2023 Filed Aug 4, 2023 00:01 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 4,590 | $92.90 | $426,411.00 |
DisclosureSEC source: 0000950170-23-038269 · ownership.xml · nonDerivative · entry 2 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 538,874 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on December 14, 2022. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $92.40 to $93.39, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 01, 2023 Filed Aug 4, 2023 00:01 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 727 | $91.91 | $66,818.57 |
DisclosureSEC source: 0000950170-23-038269 · ownership.xml · nonDerivative · entry 1 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 543,464 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on December 14, 2022. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $91.40 to $92.38, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 20:31 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 590 | $83.49 | $49,259.10 |
DisclosureSEC source: 0000950170-23-032037 · ownership.xml · nonDerivative · entry 3 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 544,191 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on December 14, 2022. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $83.40 to $83.76, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F5 · balance_after: Includes 37,332 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 20:31 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 4,653 | $82.74 | $384,989.22 |
DisclosureSEC source: 0000950170-23-032037 · ownership.xml · nonDerivative · entry 2 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 544,781 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on December 14, 2022. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $82.40 to $83.35, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 20:31 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 2,257 | $81.77 | $184,554.89 |
DisclosureSEC source: 0000950170-23-032037 · ownership.xml · nonDerivative · entry 1 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 549,434 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on December 14, 2022. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $81.40 to $82.38, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 20:34 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 1,954 | $72.21 | $141,098.34 |
DisclosureSEC source: 0000950170-23-026391 · ownership.xml · nonDerivative · entry 2 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 551,691 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on December 14, 2022. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $72.08 to $72.37, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · balance_after: Includes 37,332 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 20:34 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 5,546 | $71.44 | $396,206.24 |
DisclosureSEC source: 0000950170-23-026391 · ownership.xml · nonDerivative · entry 1 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 553,645 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on December 14, 2022. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $71.03 to $72.02, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2023 Filed May 2, 2023 22:29 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 335 | $80.12 | $26,840.20 |
DisclosureSEC source: 0000899243-23-012008 · doc4.xml · nonDerivative · entry 3 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 559,191 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on December 14, 2022. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $79.72 to $80.42, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F5 · balance_after: Includes 37,332 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 01, 2023 Filed May 2, 2023 22:29 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 1,759 | $78.65 | $138,345.35 |
DisclosureSEC source: 0000899243-23-012008 · doc4.xml · nonDerivative · entry 2 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 559,526 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on December 14, 2022. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $78.29 to $79.14, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2023 Filed May 2, 2023 22:29 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 5,406 | $77.84 | $420,803.04 |
DisclosureSEC source: 0000899243-23-012008 · doc4.xml · nonDerivative · entry 1 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 561,285 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on December 14, 2022. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $77.29 to $78.27, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 21:14 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 564 | $75.73 | $42,711.72 |
DisclosureSEC source: 0000899243-23-010442 · doc4.xml · nonDerivative · entry 3 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 566,691 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on December 14, 2022. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $75.62 to $75.93, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F5 · balance_after: Includes 37,332 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 21:14 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 3,577 | $75.14 | $268,775.78 |
DisclosureSEC source: 0000899243-23-010442 · doc4.xml · nonDerivative · entry 2 Hassanein Waleed H · CIK 0001430466 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 567,255 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on December 14, 2022. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $74.61 to $75.60, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.